Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis|
|Citation:||Alimentary Pharmacology and Therapeutics, 2016; 43(9):985-993|
|H. Philpott, S. Nandurkar, S. G. Royce, F. Thien and P. R. Gibson|
|Abstract:||Background: Elimination diets and high-dose proton pump inhibitors (PPI) are advocated as ﬁrst-line treatments in patients with eosinophilic oesophagitis (EoE). Aim: To record the treatment outcome for patients with EoE prospectively man- aged according to a clinical algorithm. Methods: Patients with oesophageal eosinophilia commenced esomeprazole 40 mg twice daily for 8 weeks. Those in histological remission were re-classiﬁed as PPI-responsive oesophageal eosinophilia. Nonresponders were offered the 6-food elimination diet with a PPI, or topical budesonide monotherapy (1 mg orally twice daily as an aqueous gel). Once disease control was achieved remission was reassessed at 3 months (all modalities) and an additional 6 months (diet group). Results: Of 107 patients who completed 8 weeks of PPI, 25 (23%) were PPI-respon- sive. 56 of 81 (69%) of patients with EoE chose the elimination diet with PPI. 29 (52%) had complete remission, 23 completed dietary reintroduction and food triggers were identiﬁed in 20 (36%). 25 chose budesonide with 23/25 (92%) responding. Remission was sustained in >85% of patients at 3 months with all treatment modalities. At 9 months, only 10/18 (55%) of patients who responded to the elimination diet with PPI remained complaint and sustained remission. Conclusions: Many patients previously diagnosed with EoE will respond to PPI. Initial response >50% is possible with the elimination diet plus PPI, but many will fail to undergo food reintroduction, or will cease the diet and relapse, resulting in only one in four patient sustaining remission at 9 months. Budesonide is very effective short term, but longer term study is needed.|
|Rights:||© 2016 John Wiley & Sons Ltd.|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.